Patients’ Portal: New Languages added
As part of our ongoing commitment to ensuring our patients are well informed about their role in the clinical trials process, Cromos Pharma has translated its patient portal into multiple new languages. In addition to currently available languages that include English, Czech, Georgian, Hungarian, Polish, Ukrainian, Russian, we have added information in Romanian, Slovak, Bulgarian, Türkiyesh, Serbian, and Kazakh languages.
Important Information about a Clinical Trial
Cromos Pharma is actively expanding its geographic coverage. We are opening multiple new offices and want our patients to be able to easily access educational materials in their native tongues. We want to make sure that they are well-informed about what it entails to participate in a clinical trial.
On our Patients’ Portal you can find information about, how to become involved, phases of research, the logistics of clinical trial conduct, about how a standard of care treatment may be impacted by a clinical trial, advantages and challenges of participation, the concept of informed consent, and important questions to ask when considering participation in a clinical trial.
Patients are at the core of what we do, and their safety and well-being always come first. An important part of ensuring patient awareness is providing easily discernible information about what it entails to become a participant in a clinical trial managed by Cromos Pharma.
We aim to understand the patient’s needs and expectations before, during and after the commencement of a trial. We feel that it is paramount to address key challenges around patient recruitment by explaining how we identify, engage and support our patients. By understanding our patients, we can assess how best to reduce the burden of participation e.g., converting on-site visits to remote or telemedicine ones, how far are patients willing to travel and what do they expect from their experience. By listening to our patients, we can identify patient-specific concerns that will impact recruitment, compliance, and retention.
Potential questions may arise regarding patients’ health records and other health information that is being accessed during a clinical trial. As the log of appointments, medical test records and test results are integral to any clinical trial, patients should be educated on confidentiality and security of their private information.
We are committed to providing all applicable information about clinical trials our patients may be interested in. Please follow our multilingual Patients’ Portal and if you still have any questions, please contact with us at email@example.com.
About Cromos Pharma
Cromos Pharma is a US-based, international contract research organization delivering fully integrated clinical research solutions, in all trial phases, across a wide range of therapeutic indications. Our expert team, comprised of 95% MDs, has extensive expertise in study design, medical writing, regulatory affairs, site management, patient recruitment and data management.
Cromos Pharma has experience in delivering success in a wide range of trial types, from biosimilars and generics, to successfully managing trials of novel therapeutics in a wide range of clinical indications. Our team provides full-service solutions to international pharma and biotech companies in high-recruiting regions, assuring exceptional data quality. Cromos Pharma combines global expertise with in-depth experience and knowledge in the US, Central and Eastern Europe, Central Asia, Republic of Georgia, and Türkiye to offer exceptional patient recruitment. Our team has met or reduced enrollment timelines in 95% of conducted trials.
We provide accelerated study start-up timelines in our regions of operation. Regulatory inspections by FDA and EMA and site audits attest to the highest quality of our clinical data.
Established in 2004, Cromos Pharma has strong regional experience that is supported by a global network of offices. Its international HQ is located in Portland, Oregon, USA and its European HQ is in Dublin, Ireland.